Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure　― Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study ―-Reference-Cited by-同舟云学术

Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure　― Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study ―

Published:2019-06-25 Issue:7 Volume:83 Page:1520-1527
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Kinugawa Koichiro¹,Sato Naoki²,Inomata Takayuki³,Yasuda Moriyoshi⁴,Shimakawa Toshiyuki⁵,Fukuta Yasuhiko⁵

Affiliation:

1. Second Department of Internal Medicine, University of Toyama

2. Department of Cardiology and Intensive Care Unit, Nippon Medical School Musashi-Kosugi Hospital

3. Department of Cardiology, Kitasato University Kitasato Institute Hospital

4. Department of Pharmacovigilance, Otsuka Pharmaceutical Co., Ltd.

5. Otsuka Pharmaceutical Co., Ltd.

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/83/7/83_CJ-19-0158/_pdf

Reference26 articles.

1. 1. Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ J 2008; 72: 489–491.

2. 2. Sato N, Kajimto K, Keida T, Mizuno M, Minami Y, Yumino D, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry). Circ J 2013; 77: 944–951.

3. 3. Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation 2018; 137: 2016–2028.

4. 4. Guidelines for diagnosis and treatment of acute and chronic heart failure (JCS 2017/JHFS 2017 [in Japanese]). https://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000202651.pdf (accessed February 20, 2019).

5. 5. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860–867.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Initial clinical experience of intravenous tolvaptan sodium phosphate in patients with congestive heart failure;Journal of Cardiology Cases;2023-04

2. Hyponatremia Associated with Congestive Heart Failure: Involvement of Vasopressin and Efficacy of Vasopressin Receptor Antagonists;Journal of Clinical Medicine;2023-02-13

3. Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure;Clinical and Experimental Nephrology;2023-02-08

4. Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan;Journal of Cardiology;2022-12

5. In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan;Journal of Pharmacological Sciences;2022-11